Search
Tarlatamab
go.drugbank.com/drugs/DB17256ApprovedInvestigational[L50748] It is a bispecific monoclonal antibody that targets CD3 expressed on the surface of T-cells and delta-like ligand 3 (DLL3), an inhibitory ligand that suppresses Notch signaling and is highly expressed … [L50743,A263808] Its bispecificity causes T-cell activation, the release of inflammatory cytokines, and lysis at DLL3-expressing cells.
Isoniazid
go.drugbank.com/drugs/DB00951ApprovedInvestigationalAntibacterial agent used primarily as a tuberculostatic. It remains the treatment of choice for tuberculosis.
Categories: Drugs for Treatment of Tuberculosis, Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeBenmoxin
go.drugbank.com/drugs/DB09246ApprovedWithdrawnBenmoxin is an irreversible and nonselective monoamine oxidase inhibitor (MAOI) of the hydrazine class. It was first synthesized in 1967 and rapidly used in Europe as an antidepressant.
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeRifalazil
go.drugbank.com/drugs/DB04934InvestigationalRifalazil is a derivative of the antibiotic rifamycin. It is being investigated by ActivBiotics for the treatment of various bacterial infections.
Categories: Drugs for Treatment of Tuberculosis, Heterocyclic Compounds with 4 or More RingsDolasetron
go.drugbank.com/drugs/DB00757ApprovedInvestigationalDolasetron is an antinauseant and antiemetic agent indicated for the prevention of nausea and vomiting associated with moderately-emetogenic cancer chemotherapy and for the prevention of postoperative … Dolasetron is a highly specific and selective serotonin 5-HT3 receptor antagonist.
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeCerliponase alfa
go.drugbank.com/drugs/DB13173ApprovedInvestigational[A264354, A264369] As a recombinant human TPP1, cerliponase alfa is used as an enzyme replacement therapy to restore the levels of TPP1 in patients with CLN2.[L51339] … [L51319] On April 27, 2017, cerliponase alfa was first approved by the FDA as the first treatment for neuronal ceroid lipofuscinosis type 2 (CLN2), also known as TPP1 deficiency.
Cycloserine
go.drugbank.com/drugs/DB00260ApprovedInvestigationalAntibiotic substance produced by Streptomyces garyphalus.
Synonyms: cyclo-D-Serine, D-CycloserineCategories: Drugs for Treatment of TuberculosisTeduglutide
go.drugbank.com/drugs/DB08900ApprovedInvestigationalTeduglutide is a glucagon-like peptide-2 (GLP-2) analogue. It is made up of 33 amino acids and is manufactured using a strain of Escherichia coli modified by recombinant DNA technology. … The significance of this substitution is that teduglutide is longer acting than endogenous GLP-2 as it is more resistant to proteolysis from dipeptidyl peptidase-4. FDA approved on December 21, 2012.
Categories: Compounds used in a research, industrial, or household settingZavegepant
go.drugbank.com/drugs/DB15688ApprovedInvestigationalZavegepant is a third-generation CGRP receptor antagonist that is small in size and highly soluble. Due to its pharmacological properties, it can be administered intranasally. … [A258190,A258195] In March 2023, the FDA approved the use of zavegepant nasal spray for the acute treatment of migraine with or without aura in adults.
Decamethonium
go.drugbank.com/drugs/DB01245ApprovedIt is a short acting depolarizing muscle relaxant. It is similar to acetylcholine and acts as a partial agonist of the nicotinic acetylcholine receptor.